Eurofins Discovery provides Integrated Drug Discovery (IDD) services to support small molecule and biologics programs from early discovery through preclinical candidate selection and IND-enabling.
Our IDD model brings together expert scientific leadership, multidisciplinary expertise, global infrastructure and dedicated project management to enable efficient execution and data-driven decision-making at each stage of drug discovery.
Why work with us?
- Integrated, end‑to‑end discovery under a unified scientific vision
- IDD expertise with clinically validated outcomes – meet the experienced team
- Flexible programs tailored to client’s needs
- Faster, data‑driven decisions with fewer handoffs
- Backed by Eurofins’ global discovery capabilities
Eurofins Discovery brings particular strength in GPCR drug discovery, while supporting IDD programs across a broad range of target classes and therapeutic areas, such as Oncology, Inflammation, CNS, Metabolic disorders, and many more.
Integrated Discovery Capabilities
Eurofins Discovery IDD programs combine:
- Hit finding, including virtual screening and high-throughput approaches
- Medicinal, computational and synthetic chemistry, supporting IP generation during hit-to-lead and lead optimization
- Biology, ADMET, and translational science, including custom assay development and early risk assessment
- In vivo pharmacology, 350+validated models across all major therapeutic areas, etc.)
- Experience of diverse modalities: including small molecules, peptides, macrocycles, natural product-like, degraders, steroidal scaffolds, ADCs, proteins, antibodies and more
Capabilities are tailored to program objectives, target class, and stage of discovery.
Check our videos on our youtube channel.
What We Offer – The Eurofins Discovery IDD Model, DiscoveryOne™
Accelerating Drug Discovery with the Extensive Eurofins Network: Innovative Solutions, Enhanced Collaboration, Faster Timelines
- Alignment on program goals and key milestones
- Discovery strategy and screening cascade design and consultation
- Early Target Product Profile definition
- Competitive landscape evaluation
- Data‑driven compound prioritization
Flexible Engagement Model
We offer flexible engagement models FFS, FTE, or hybrid models, with the option to include a success incentive for pre agreed project milestones. FTE models provide access to dedicated scientific expertise, enabling clients to extend their internal discovery capabilities without investing in full infrastructure.
Satisfied Clients
“Thanks to you and the whole Eurofins team. This has been a very productive collaboration. Together your teams have really helped us move forward with screening our chemistry library….We really like working with you guys, you are the CRO generating data of the highest quality… We like the DiscoveryOne concept and knowing that when it is in your hands we don’t have to worry. Meeting format is perfect for our needs.”
– US Biotech
“I really like how you make your team available on a regular basis. Eurofins is a great organization with a lot of expertise and good coordination…. The faster I can get and analyze my data the more efficiently I can move my program.”
– US AI Company
Integrated Drug Discovery: FAQs
What experience does Eurofins Discovery have with integrated GPCR drug discovery?
Eurofins Discovery’s GPCR IDD capability is strengthened by Beacon Discovery – acquired in 2021 – which has delivered multiple clinical candidates and contributed to marketed GPCR-targeted therapeutics.
What scientific disciplines are included within Eurofins Discovery’s IDD offering?
IDD programs are supported by fully integrated biology, medicinal and computational chemistry, DMPK, structural biology, in vitro pharmacology, and translational sciences -ensuring data‑driven decision making from hit finding through preclinical candidate selection.
Can clients access individual capabilities without engaging in a full IDD program?
Yes. While many partners benefit from the fully integrated model, Eurofins Discovery also provides all capabilities as standalone services, allowing clients to plug into specific expertise where needed.
What therapeutic areas are best suited for IDD?
IDD is modality-agnostic and disease-area agnostic, but is especially impactful in neuroscience, immunology, oncology, metabolic diseases, and GPCR-related biology – areas where Eurofins Discovery brings deep expertise.
How does IDD accelerate program timelines?
IDD reduces inefficiencies caused by cross-vendor handoffs, ensures continuous data flow between disciplines, and enables faster decision making through unified project management and shared scientific strategy.
How do Eurofins Discovery teams collaborate with clients?
Clients receive direct access to dedicated project leadership, scientific leads, and discipline experts, with regular data reviews, strategic planning sessions, and transparent reporting to ensure alignment on milestones and next steps.
Advance Your Discovery Program
Whether you are validating a novel target or advancing a lead toward candidate selection, Eurofins Discovery IDD services provide scientific leadership, expertise, and infrastructure to support your next preclinical milestone.
